Free Trial

Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock Position Raised by JPMorgan Chase & Co.

Regulus Therapeutics logo with Medical background

JPMorgan Chase & Co. lifted its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 141.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 190,457 shares of the biopharmaceutical company's stock after acquiring an additional 111,485 shares during the period. JPMorgan Chase & Co. owned approximately 0.29% of Regulus Therapeutics worth $301,000 as of its most recent SEC filing.

Separately, Barclays PLC raised its stake in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after purchasing an additional 62,549 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RGLS has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Friday, March 14th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $9.00 target price on shares of Regulus Therapeutics in a research report on Thursday, May 1st. Leerink Partnrs downgraded Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Canaccord Genuity Group restated a "hold" rating and set a $11.00 price objective (down from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Finally, Leerink Partners reiterated a "market perform" rating and set a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.50.

View Our Latest Analysis on Regulus Therapeutics

Regulus Therapeutics Stock Performance

NASDAQ RGLS remained flat at $7.85 during trading hours on Thursday. The company's stock had a trading volume of 121,634 shares, compared to its average volume of 1,501,296. The company has a market cap of $520.01 million, a price-to-earnings ratio of -7.34 and a beta of 0.49. Regulus Therapeutics Inc. has a 1 year low of $0.83 and a 1 year high of $8.20. The business has a fifty day moving average of $2.50 and a two-hundred day moving average of $1.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). During the same quarter last year, the business earned ($0.40) EPS. On average, equities research analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Regulus Therapeutics Profile

(Free Report)

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

Read More

Institutional Ownership by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Should You Invest $1,000 in Regulus Therapeutics Right Now?

Before you consider Regulus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.

While Regulus Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines